Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy

Leukemia and Lymphoma

Volumn 21, Issue 1-2, 1996, Pages 63-70

  Carella, Angelo Michele ^a   Prencipe, Emma ^a   Pungolino, Ester ^a   Lerma, Enrica ^a   Frassoni, Francesco ^a   Rossi, Edoardo ^a   Giordano, Domenico ^a   Occhini, Domenico ^a   Gatti, Anna M ^a   Bruni, Roberta ^a   Spriano, Mauro ^a   Nati, Sandro ^a   Pierluigi, Daniela ^a   Congiu, Marina ^a   Vimercati, Renato ^a   Ravetti, Jean Louis ^a   Federico, Massimo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

High dose therapy in first remission; High risk Hodgkin's disease

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; AUTOGRAFT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

EID: 13344250467     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609067581     Document Type: Article

References (16)

1. Carella, A. M., Carlier, P., Congiu, A. et al. (1991) Autologous BMT as adjuvant therapy for high risk Hodgkin's disease in first remission after MOPP-ABVD protocol. Bone Marrow Transplantation, 8, 99-103.
2. Bonadonna, G., Valagussa, P., Santoro, A. et al. (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann. Intern. Med., 104, 739-746.
3. Jagannath, S., Dicke, K. A., Armitage, J. O. et al., (1986) High-dose cyclophosphamide. carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin' s disease. Ann. Intern. Med., 104, 163-168.
4. Carella, A.M., Congiu, A., Occhini, D. et al., (1991) Nine years experience with ABMT in 128 patients with Hodgkin's disease of the Italian Cooperative Study Group. In: Fifth Intern. Symposium: Autologous Bone Marrow Transplantation. Dicke KA., Armitage JO. (eds). Nebraska University, Omaha pp. 509-518.
5. Henry-Amar, M., Sommers, R. (1990) Survival outcome after Hodgkin's disease: A report from the International data base on Hodgkin's disease. Semin. Oncol., 17, 758-768.
6. Canellos, G. P., Anderson, J. R., Propert, K. J. et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New Engl. J. Med., 327, 1478-1484.
7. Carde, P., Bergsagel, D. E., Nissen, N. I. et al. (1990) The treatment of advanced Hodgkin's disease: strategy. In: Treatment strategy in Hodgkin's disease, Colloque INSERM Vol. 196, edited by Somers R., Henry-Amar M., Meerwaldt, J. H., Carde, P., London, Paris, Les Editions INSERM: John Libbey, Eurotext LTD. 196, 105-108.
8. Carde, P. (1995) Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments? Leukemia and Lymphoma, 15(suppl. 1), 31-40.
9. Klimo, P. (1995) Evolution of the concept of prognostication in therapy of Hodgkin' s Lymphoma. Leukemia and Lymphoma, 15(Suppl. 1), 15-18.
10. Hasenclever, D., Schmilz, N., Loeffler, M. et al. (1994) Advanced Hodgkin's disease in first CR or PR: Do parameters present at diagnosis identify a high risk group qualifying for autologous stem cell transplantation? Proc. ASCO 13, 1279 (abstr).
11. Reece, D. E., Connors, J. M., Spinelli, J. J. et al. (1994) Intensive therapy with cyclophosphamide, carmustine, etoposide, ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood, 83, 1193-1199.
12. Strauss, D. J., Gaynor, J. J., Myers, J. et al. (1990) Prognostic Factors among 185 adult with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J. Clin. Oncol., 7, 1173-1176.
13. Bradley, S. J., Pearce, R., Taghipour, G. et al. (1995) First remission autologous bone marrow transplantation for Hodgkin' s disease, preliminary EBMT data. Leukemia and Lymphoma, 15(Suppl. 1), 51-53.
14. Sureda, A., Burnet, S., Lopez, J. J., et al. (1992) High-dose chemotherapy with bone marrow rescue for treatment of Hodgkin's Disease. Leukemia & Lymphoma, 7(suppl.), 29-31.
15. Moreau, P., Milpied, N., Mechinaud-Lacroix, F. (1993) Early intensive therapy with autotransplantation for high-risk Hodgkin's disease. Leukemia & Lymphoma, 12, 51-58.
16. Federico, M., Clò, V. and Carella, A. M. (1995) Preliminary analysis of clinical characteristics of patients enrolled in the HD01 Protocol: A randomised trial of High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's disease responding to first line therapy. Leukemia and Lymphoma, 15(Suppl. 1), 63-66.